Lithium Treatment Induces Cardiac Dysfunction in Mice

Int J Mol Sci. 2023 Nov 1;24(21):15872. doi: 10.3390/ijms242115872.

Abstract

Lithium (Li) salts are commonly used as medications for bipolar disorders. In addition to its therapeutic value, Li is also being increasingly used as a battery component in modern electronic devices. Concerns about its toxicity and negative impact on the heart have recently been raised. We investigated the effects of long-term Li treatment on the heart, liver, and kidney in mice. Sixteen C57BL/6J mice were randomly assigned to receive oral administration of Li carbonate (n = 8) or act as a control group (n = 8) for 12 weeks. We evaluated the cardiac electrical activity, morphology and function, and pathways contributing to remodelling. We assessed the multi-organ toxicity using histopathology techniques in the heart, liver, and kidney. Our findings suggest that mice receiving Li had impaired systolic function and ventricular repolarisation and were more susceptible to arrhythmias under adrenergic stimulation. The Li treatment caused an increase in the cardiomyocytes' size, the modulation of the extracellular signal-regulated kinase (ERK) pathway, along with some minor tissue damage. Our findings revealed a cardiotoxic effect of Li at therapeutic dosage, along with some histopathological alterations in the liver and kidney. In addition, our study suggests that our model could be used to test potential treatments for Li-induced cardiotoxicity.

Keywords: ERK1/2; cardiac function; cardiotoxicity; lithium pollution; lithium therapy; mouse.

MeSH terms

  • Animals
  • Antimanic Agents* / therapeutic use
  • Cardiotoxicity / drug therapy
  • Lithium Compounds
  • Lithium* / toxicity
  • Mice
  • Mice, Inbred C57BL

Substances

  • Lithium
  • Antimanic Agents
  • Lithium Compounds